IL156549A0 - Method and composition for the treatment of diabetic neuropathy - Google Patents

Method and composition for the treatment of diabetic neuropathy

Info

Publication number
IL156549A0
IL156549A0 IL15654901A IL15654901A IL156549A0 IL 156549 A0 IL156549 A0 IL 156549A0 IL 15654901 A IL15654901 A IL 15654901A IL 15654901 A IL15654901 A IL 15654901A IL 156549 A0 IL156549 A0 IL 156549A0
Authority
IL
Israel
Prior art keywords
diabetic neuropathy
treatment
compositions
composition
symptoms
Prior art date
Application number
IL15654901A
Other languages
English (en)
Original Assignee
The Quigley Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/740,811 external-priority patent/US6555573B2/en
Priority claimed from US09/847,121 external-priority patent/US20020165207A1/en
Application filed by The Quigley Corp filed Critical The Quigley Corp
Publication of IL156549A0 publication Critical patent/IL156549A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL15654901A 2000-12-21 2001-12-19 Method and composition for the treatment of diabetic neuropathy IL156549A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/740,811 US6555573B2 (en) 2000-12-21 2000-12-21 Method and composition for the topical treatment of diabetic neuropathy
US09/847,121 US20020165207A1 (en) 2001-05-02 2001-05-02 Compositions and methods for the treatment of diabetic neuropathy
PCT/US2001/049297 WO2002049575A2 (en) 2000-12-21 2001-12-19 Method and composition for the treatment of diabetic neuropathy

Publications (1)

Publication Number Publication Date
IL156549A0 true IL156549A0 (en) 2004-01-04

Family

ID=27113759

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15654901A IL156549A0 (en) 2000-12-21 2001-12-19 Method and composition for the treatment of diabetic neuropathy

Country Status (11)

Country Link
EP (1) EP1351679B1 (xx)
JP (1) JP4411414B2 (xx)
AT (1) ATE456957T1 (xx)
AU (2) AU3109502A (xx)
CA (1) CA2431079C (xx)
DE (1) DE60141253D1 (xx)
ES (1) ES2340363T3 (xx)
IL (1) IL156549A0 (xx)
MX (1) MXPA03005672A (xx)
NZ (1) NZ526041A (xx)
WO (1) WO2002049575A2 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
IL162505A0 (en) * 2001-12-19 2005-11-20 The Quigley Corp Method for treatment of peripheral neural and vascular ailments
DE10244282A1 (de) * 2002-09-23 2004-04-01 Merck Patent Gmbh Zubereitung mit antioxidanten Eigenschaften
FR2844716B1 (fr) * 2002-09-23 2008-11-21 Marcel Jacques Chicouri Nouvelles compositions pharmaceutiques destinees notamment a l'hygiene des pieds des diabetiques
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
AU2004312072B2 (en) * 2003-12-29 2011-06-23 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
JP2006083138A (ja) * 2004-09-17 2006-03-30 Suntory Ltd アルドース還元酵素阻害剤
JP2006089399A (ja) * 2004-09-22 2006-04-06 Hajime Fukuda 2型糖尿病治療剤
JP2006298808A (ja) * 2005-04-19 2006-11-02 Hayashibara Biochem Lab Inc 痛覚刺激緩和剤
JP2006335752A (ja) * 2005-06-01 2006-12-14 Oriza Yuka Kk アルドース還元酵素阻害剤
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
EP1939166A1 (en) * 2006-12-19 2008-07-02 InterMed Discovery GmbH Plants extracts for use in brain modulation
DE102007029042A1 (de) * 2007-06-21 2008-12-24 Analyticon Discovery Gmbh Pharmazeutische Zusammensetzung mit einem Trihydroxychromenone-Derivate
JP4932776B2 (ja) * 2008-04-16 2012-05-16 花王株式会社 油脂組成物
WO2011055869A1 (ko) * 2009-11-05 2011-05-12 한국 한의학 연구원 소석적려를 이용한 당뇨합병증 치료 및 예방용 조성물
JP6151003B2 (ja) * 2012-10-26 2017-06-21 学校法人近畿大学 カンカニクジュヨウから得られる抗糖尿病剤、ヒト又は動物用医薬および機能性食品
KR101510257B1 (ko) 2013-12-30 2015-04-09 한림대학교 산학협력단 크리신(chrysin)을 유효성분으로 하는 당뇨합병성 신세뇨관 섬유화로 인한 신장섬유증 억제용 조성물
CN117298133B (zh) * 2023-11-30 2024-02-23 唐宁医药科技(济南)有限公司 归知糖疽有效成分配方在制备治疗糖尿病足药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250097A (en) * 1978-03-08 1981-02-10 Syntex (U.S.A.) Inc. Compositions for and a method of preventing diabetic complications
FR2543550B1 (fr) * 1983-04-01 1985-08-09 Cortial Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique
US6103709A (en) * 1993-12-23 2000-08-15 The Regents Of The University Of California Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs and methods for treatment of vitamin D diseases
US5948443A (en) * 1996-02-23 1999-09-07 Medical Doctor's Research Institute, Inc. Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease
GB9827391D0 (en) * 1998-12-11 1999-02-03 Fundation O N C F Aldose reductase inhibitors and pharmaceutical compositions
JP2002541116A (ja) * 1999-04-05 2002-12-03 ジーグラー,ランディー,エイチ 糖尿病の治療のための組成物及び方法
US6103756A (en) 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals

Also Published As

Publication number Publication date
ES2340363T3 (es) 2010-06-02
JP4411414B2 (ja) 2010-02-10
AU3109502A (en) 2002-07-01
CA2431079A1 (en) 2002-06-27
NZ526041A (en) 2005-01-28
EP1351679A2 (en) 2003-10-15
ATE456957T1 (de) 2010-02-15
WO2002049575A2 (en) 2002-06-27
WO2002049575A3 (en) 2003-07-24
DE60141253D1 (de) 2010-03-25
AU2002231095B2 (en) 2005-11-24
CA2431079C (en) 2010-02-09
MXPA03005672A (es) 2004-12-03
JP2004516257A (ja) 2004-06-03
EP1351679A4 (en) 2007-03-21
EP1351679B1 (en) 2010-02-03

Similar Documents

Publication Publication Date Title
AU3109502A (en) Method and composition for the treatment of diabetic neuropathy
MXPA04006039A (es) Metodo para el tratamiento de afecciones vasculares y neuronales perifericas.
WO2001024763A3 (en) Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
MXPA03010146A (es) Composiciones de lipidos hipotensivos (derivados de prostaglandina) y timolol, y metodos para usar las mismas.
HK1091481A1 (en) Therapeutic agents useful for treating pain
AUPR177300A0 (en) Therapeutic methods
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO2007002862A3 (en) Compositions and methods for treatment of cycle-related symptoms
TW200639159A (en) Treatment of pain
WO2003072066A3 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
WO2002009702A8 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
BG103780A (en) Antitussive compositions
WO1992019617A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
WO2001012169A3 (en) Method of cancer treatment
AU2002357191A1 (en) Derivatives of isoindigo, indigo and indirubin and use in treating cancer
AU5170400A (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
AU2002314056A1 (en) Use of a vitamin d3 analogue for the treatment of autoimmune diabetes
WO2000048446A3 (en) Use of antagonists of pg-e for the treatment of neuropathic pain
IL156169A0 (en) Use of 6-dimethylaminomethyl-1-phenylcyclohexane compounds for treating urinary incontinence
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
WO2001007029A3 (en) Substituted guanidines and the use thereof
CA2458690A1 (en) Pharmaceutical compositions comprising an ascomycin derivative